Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.
作者信息
Parra-Lara Luis Gabriel, Martinez-Arboleda Juan José, Isaza-Pierotti Daniel Francisco, Rosso Fernando
机构信息
Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia.
Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia.
出版信息
Int J Antimicrob Agents. 2021 Jan;57(1):106172. doi: 10.1016/j.ijantimicag.2020.106172.
Abstract
摘要
相似文献
1
Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.羟氯喹治疗新型冠状病毒肺炎的疗效评估：一项开放标签非随机临床试验的二次分析
Int J Antimicrob Agents. 2021 Jan;57(1):106172. doi: 10.1016/j.ijantimicag.2020.106172.
2
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited.羟氯喹和阿奇霉素用于治疗新型冠状病毒肺炎：重新审视一项开放标签非随机临床试验的结果
Int J Antimicrob Agents. 2021 Jan;57(1):106243. doi: 10.1016/j.ijantimicag.2020.106243.
3
Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".致编辑的信：关于“羟氯喹和阿奇霉素作为治疗新型冠状病毒肺炎的药物：一项开放标签非随机临床试验的结果”
Int J Antimicrob Agents. 2021 Jan;57(1):106171. doi: 10.1016/j.ijantimicag.2020.106171.
4
Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial.参考研究：《羟氯喹和阿奇霉素治疗新型冠状病毒肺炎：一项开放标签非随机临床试验的结果》
Int J Antimicrob Agents. 2021 Jan;57(1):106176. doi: 10.1016/j.ijantimicag.2020.106176.
5
Advanced statistical methods and designs for clinical trials for COVID-19.用于新型冠状病毒肺炎临床试验的先进统计方法与设计
Int J Antimicrob Agents. 2021 Jan;57(1):106167. doi: 10.1016/j.ijantimicag.2020.106167.
6
Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".关注“羟氯喹和阿奇霉素治疗新型冠状病毒肺炎：一项开放标签非随机临床试验的结果”的临床结局。
Int J Antimicrob Agents. 2021 Jan;57(1):106175. doi: 10.1016/j.ijantimicag.2020.106175.
7
Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.羟氯喹和阿奇霉素对新型冠状病毒肺炎患者严重急性呼吸综合征冠状病毒2清除率的影响：一项荟萃分析
Int J Antimicrob Agents. 2021 Jan;57(1):106240. doi: 10.1016/j.ijantimicag.2020.106240.
8
Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients.羟氯喹啉与阿奇霉素联合治疗COVID-19患者的安全性概况。
Int J Antimicrob Agents. 2021 Jan;57(1):106236. doi: 10.1016/j.ijantimicag.2020.106236.
9
Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load.羟氯喹和阿奇霉素对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒载量的影响尚不确定。
Int J Antimicrob Agents. 2021 Jan;57(1):106169. doi: 10.1016/j.ijantimicag.2020.106169.
10
Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.近期文献不支持将羟氯喹与阿奇霉素联合用于新冠肺炎患者。
Int J Antimicrob Agents. 2021 Jan;57(1):106174. doi: 10.1016/j.ijantimicag.2020.106174.
引用本文的文献
1
Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.羟氯喹对新型冠状病毒肺炎疗效评估的回应：一项开放标签非随机临床试验的二次分析
Int J Antimicrob Agents. 2021 Jan;57(1):106237. doi: 10.1016/j.ijantimicag.2020.106237.
本文引用的文献
1
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
Zotero 插件